G&E Herbal Biotechnology Co., Ltd. (4911.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
26.60 TWD
Market cap
1.98 bn TWD
P/E (2025)
14.20
P/S (2025)
6.40
Dividend yield
4.38 %
Net margin
45.03 %
Return on equity (ROE)
15.00 %
Return on assets (ROA)
14.27 %

G&E Herbal Biotechnology Co., Ltd. financials

Fiscal year20242025
Revenue249.03 m TWD309.13 m TWD
Gross profit205.34 m TWD263.22 m TWD
Operating income119.65 m TWD152.30 m TWD
EBIT124.77 m TWD158.42 m TWD
Net income102.06 m TWD139.20 m TWD
Diluted EPS – continuing operations1.48 TWD2.02 TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About G&E Herbal Biotechnology Co., Ltd.

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.